CMMB
Chemomab Therapeutics Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 19 ▲ Chemomab Therapeutics reported its full-year and Q4 2025 financial r…
- May 29 ▲ 1 insider buy $20.2K at $2.07
- Jul 8 ▲ Chemomab Therapeutics (CMMB) entered into a definitive merger agreem…
- Aug 14 ▲ Short interest falls 27.3% to 113.2K
- Aug 19 Chemomab reported Q2 2026 financial results and provided a corporate…
- Aug 19 ▼ Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss v…
- Aug 27 to Aug 28 ▼ 2 days of insider sells: $6.5K by 1 insider, avg $2.83
- Sep 30 ▲ Short interest falls 87.1% to 10.5K
- Oct 15 ▼ Short interest jumps 31.7% to 13.9K
- Oct 30 ▲ Short interest falls 63.0% to 5.1K
- Oct 30 Chemomab Therapeutics Ltd. filed a definitive proxy statement for a…
- Nov 2 M&A: Chemomab Therapeutics and Scipher Medicine Announce SEC Re…
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $20.2K at an average $2.07. 1 insider sold $6.5K. Price is 22% below their cost.
- InstitutionsMIXED
Q3 2026: 0 added (0 new), 2 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.010 → $0.000 over 90 days. 1 up, 0 down in 30 days.
- Short sellersCOVERING
Short interest −63.0% to 5.1K shares. 1.0 days to cover, ≈0.1% of shares.
- TrendRANGE
1% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $3.9K |
| MORGAN STANLEY | TRIM | $1.9K |
| CITADEL ADVISORS LLC | ADD | $154.4K |
| RHUMBLINE ADVISERS | ADD | $49.5K |
| UBS Group AG | NEAR_EXIT | $13.00 |
| RHUMBLINE ADVISERS | ADD | $29.5K |
| JANE STREET GROUP, LLC | TRIM | $25.7K |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $13.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2025Price is below the lowest target. Median implies +209%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 27, 2025 | Oppenheimer MAINTAIN | Outperform |
| May 16, 2025 | Oppenheimer MAINTAIN | Outperform |
| Feb 20, 2025 | Maxim Group MAINTAIN | Buy |
| Nov 15, 2024 | Oppenheimer REITERATE | Outperform |
| May 13, 2024 | Maxim Group INITIATE | Buy |
| May 6, 2024 | Oppenheimer UPGRADE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Cohen Neil Harris Director Aug 28, 2026 | SELL | $2.8K |
Cohen Neil Harris Director Aug 27, 2026 | SELL | $3.7K |
Mor George Adi Chief Executive Officer May 29, 2026 | BUY | $10.0K |
Mor George Adi Chief Executive Officer May 29, 2026 | OTHER | 31,712 sh |
Mor George Adi Chief Executive Officer May 29, 2026 | BUY | $10.2K |
Mor George Adi Chief Executive Officer May 29, 2026 | OTHER | 18,750 sh |
Cohen Neil Harris Director Mar 16, 2026 | AWARD | 5,172 sh |
Cohen Neil Harris Director Mar 16, 2025 | AWARD | 3,821 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | No data | $0.00 |
| Next Q | $0.00 | $0.00–$0.00 | No data | $0.00 |
| Current FY | -$0.02 | -$0.02–-$0.02 | +0.0% | $0.00 |
| Next FY | -$0.03 | -$0.03–-$0.03 | +0.0% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 2 press releases · 1 bullish · 1 bearish · 11 neutral- NEUTRAL SC 13DNov 10, 2026
Scipher Medicine Corporation filed a Schedule 13D disclosing beneficial ownership of 74,576,240…
Monitor the merger timeline and any amendments to the Merger Agreement. The note holders' conversion terms and the CVR distribution will determine the ultimate value transfer. Watch for any…
- NEUTRAL DEFA14ANov 10, 2026
Chemomab Therapeutics filed a DEFA14A supplement to its proxy statement/prospectus for the…
The supplement updates the exchange ratio and ownership percentages for the merger, but does not change the vote mechanics or meeting date. The key event to watch is the December 4, 2026 shareholder…
- NEUTRAL 6-KNov 3, 2026
Chemomab Therapeutics filed a Form 6-K to incorporate by reference into its registration…
The effective S-4 and this incorporation filing signal the merger is progressing toward a shareholder vote and closing. Monitor for the record date, proxy mailing, and shareholder meeting…
- NEUTRAL PRESS RELEASENov 2, 2026
Chemomab Therapeutics announced that the SEC declared effective the S-4 registration statement for…
Monitor the December 4 shareholder vote and any updates on the private placement financing. The CVR milestones for nebokitug in RA will be a key value driver post-merger.
All CMMB filing & press-release reports (15)
- SC 13D reportNov 10, 2026
- DEFA14A reportNov 10, 2026
- 6-K reportNov 3, 2026
- PRESS-RELEASE reportNov 2, 2026
- DEFM14A reportOct 30, 2026
- 6-K reportOct 19, 2026
- 6-K reportSep 30, 2026
- 6-K reportAug 19, 2026
- PRESS-RELEASE reportAug 19, 2026
- 6-K reportJul 8, 2026
- 6-K reportJun 2, 2026
- PRESS-RELEASE reportMay 14, 2026
- 6-K reportMay 14, 2026
- 6-K reportMay 6, 2026
- PRESS-RELEASE reportMar 19, 2026